Anavex Life Sciences presented new data from the ANAVEX®2-73-AD-004 Phase IIb/III program and the long-term open-label extension of ANAVEX®2-73-AD-EP-004 at the AD/PD 2026 conference, showing a consistent correlation between maintenance of MRI-defined brain volumes.
A dedicated MRI biomarker analysis showed slowing of atrophy with improvements in ADAS-Cog13, ADCS-ADL, and CDR-SB, and in the genetically defined ABCLEAR3 (SIGMAR1 and COL24A1 wild-type) population, the correlation strength for ADAS-Cog13 improved by 78%, increasing R² from 13 to 40.3%.
According to the company, long-term clinical data show a time saving of 77.4 weeks (17.8 months) compared to control ADNI 1 after 144 weeks (33.1 months) of treatment. The presentation, conducted by Professor Timo Grimmer and colleagues, highlighted oral administration and controlled tolerance as practical advantages for patients and families.
The release describes the findings as exploratory evidence and not conclusive evidence of efficacy or safety, and positions the results as support for Anavex Life Sciences’ precision medicine strategy for early-onset Alzheimer’s disease.
Post Blarkamesine correlates functional and cognitive outcomes in the AD-004 trial appeared first Long time. Technology.
